New FDA draft guidance suggests the inclusion of patients with HIV, hepatitis B and hepatitis C in cancer clinical trials based on predetermined conditions. The guidelines are being revised because too tightly defined criteria deter patient recruitment, which affects all other factors of a drug testing trial, including publication of data.
FDA releases draft guidance on eligibility criteria for cancer trials
Sign up for FasterCures SmartBrief
Medical research news
Get the intelligence you need: news and information that is changing your industry today, hand-curated by our professional editors from thousands of sources and delivered straight to your inbox.